Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark

Rønborg, Steen; Johnsen, Carsten; Theilgaard, Sune A.; Winther, A.M.L.; Hahn-Pedersen, Julie; Andreasen, Jakob Nørgaard; Olsen, Jens

doi:10.3111/13696998.2016.1158718

Cited by 16 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…this assumption is a limitation of this analysis. However, a CMA was determined to be the most feasible and appropriate type of economic analysis, as this assessment method has also been used in similar studies [34][35][36]. Costs and resource use included in the analysis were solely associated with the treatments and treatment administration, including direct and indirect costs.…”

Section: Discussionmentioning

confidence: 99%

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Ellis

Gagnon

Hammerby

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: A cost-minimization analysis (CMA) was performed to evaluate the economic implications of introducing the SQ Tree sublingual immunotherapy (SLIT)-tablets marketed as ITULATEK® (Health Canada regulatory approval in April 2020) for the treatment of pollen-induced (birch, alder and/or hazel) seasonal allergic rhinitis in Canada (Ontario and Quebec), where Tree Pollen subcutaneous immunotherapy (SCIT) is already an available treatment option.Methods: A CMA was deemed appropriate and was based on the assumption that the SQ Tree SLIT-tablets have comparable efficacy to Tree Pollen SCIT. A societal perspective was adopted in the model, including relevant costs of medications, costs of health care services, and productivity losses. The time horizon in the model was three years, which corresponds to a minimal treatment course of allergy immunotherapy. Resource use and costs were based on published sources, where available, and validated by Canadian specialist clinicians (allergists) in active practice in Ontario and in Quebec, where applicable. A discount rate of 1.5% was applied in accordance with the Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines. To assess the robustness of the results, scenario analyses were performed by testing alternative assumptions for selected parameters (e.g., Tree Pollen SCIT resource use, discount rates, number of injections, annual SCIT dosing with maintenance injections, and nurse time support), to evaluate their impact on the results of the analysis.Results: The direct costs, including the drug costs, physician and nursing services costs, for three years of treatment, were similar for both SQ Tree SLIT-tablets vs. Tree Pollen SCIT in both Ontario and Quebec ($2,799.01 and $2,838.70 vs. $2,813.41 and $2771.81, respectively). However, when the indirect costs (including patient’s travel expenses and lost working hours) are included in the model, total savings for the treatment with SQ Tree SLIT-tablets of $1,691.44 for Ontario and $1,705.63 for Quebec were observed. Scenario analyses were conducted and showed that changes in assumptions continue to result in the savings of SQ Tree SLIT- tablets over Tree Pollen SCIT. Conclusions: The CMA indicates that SQ Tree SLIT-tablets are a cost-minimizing alternative to Tree Pollen SCIT when considered from a societal perspective in Ontario and Quebec.

show abstract

Section: Discussionmentioning

confidence: 99%

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Ellis

Gagnon

Hammerby

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Among treatment options for AR, AIT (that includes SCIT and SLIT) has exclusive features, that include the ability to alter the natural history of allergy and to extend its effectiveness, differently from drug treatment, to several years after discontinuing the therapy. A growing bulk of data indicates that SCIT and SLIT may be very advantageous to the healthcare systems [35–38]. However, the pharmacoeconomic advantage demonstrated in optimally performed studies needs to be confirmed by real-life experiences.…”

Section: Discussionmentioning

confidence: 99%

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

et al. 2017

View full text Add to dashboard Cite

Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the management of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy (SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass pollen tablets.

show abstract

“… 24 Previous economic comparisons of SCIT and SLIT‐tablets for individuals with allergies to other allergens have also been conducted as cost‐minimization analyses. 25 , 26 …”

Section: Methodsmentioning

confidence: 99%

ITULAZAX^® versus Alutard SQ^® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective

Rønborg

Grand

Brandi

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background and aims Allergic rhinitis (AR) is an inflammatory disorder triggered by an allergic immune response to inhaled allergens. Birch pollen is the major allergenic tree pollen in parts of Europe. ITULAZAX® is a sublingual immunotherapy tablet for the treatment of adults with moderate‐to‐severe AR and/or conjunctivitis induced by pollen from the birch homologous group. The aim was to compare the costs of treating AR with ITULAZAX® versus subcutaneous ALUTARD SQ® Betula verrucosa (ALUTARD SQ®) from a Danish societal perspective. Methods A cost‐minimization model was developed to capture costs of allergy immunotherapy (AIT), interactions with healthcare professionals (HCPs) in three different care settings (general practice, allergy specialist, and hospital), and indirect costs arising from absenteeism and presenteeism. The cost‐minimization analysis was conducted over a 3‐year time horizon with costs reported in 2021 Danish Kroner (DKK) and Euros (EUR) based on the European Central Bank 365‐day average exchange rate. One‐way sensitivity analyses were performed. Results The base case analysis showed that the total cost of treatment over 3 years was estimated to be DKK 49,117 (EUR 6598) per patient with ALUTARD SQ®, compared with DKK 30,996 (EUR 4164) with ITULAZAX®, reflecting a cost saving of DKK 18,121 (EUR 2434) per patient with ITULAZAX® over 3 years. Over the 3‐year time horizon, costs of AIT were predicted to increase by DKK 17,928 (EUR 2408) with ITULAZAX®, while costs of interactions with HCPs were predicted to decrease by DKK 22,528 (EUR 3027) versus ALUTARD SQ®, more than offsetting the increased cost of ITULAZAX®. Conclusions Given the equivalent effectiveness of the two AIT products, and the cost savings with ITULAZAX® versus ALUTARD SQ® from a Danish societal perspective, ITULAZAX® should be considered as a cost‐saving alternative to ALUTARD SQ® for the treatment of birch pollen‐induced moderate‐to‐severe AR in adults.

show abstract

Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark

Cited by 16 publications

References 12 publications

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

ITULAZAX^® versus Alutard SQ^® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective

Contact Info

Product

Resources

About

Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark

Cited by 16 publications

References 12 publications

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Sublingual Immunotherapy Tablet – a Cost-minimizing Alternative in the Treatment of Tree Pollen-induced Seasonal Allergic Rhinitis in Canada

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

ITULAZAX® versus Alutard SQ® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective

Contact Info

Product

Resources

About

ITULAZAX^® versus Alutard SQ^® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective